Soligenix (NASDAQ:SNGX) CEO Chris Schaber joined Steve Darling from Proactive to share news the company has been very busy over the last moths with some major accomplishments including an agreement from the FDA on an initial pediatric study plan for HyBryte for the treatment of CTCL. Schaber also told Proactive the company announced it had signed a worldwide exclusive license to supply its ricin antigen to SERB Pharmaceuticals, for development of a novel therapeutic treatment against ricin toxin poisoning.
Soligenix hits some major milestones in 2022 including FDA approval for Pediatric study plan on HyBryte
